108 related articles for article (PubMed ID: 24689821)
1. Exploring the water-binding pocket of the type II dehydroquinase enzyme in the structure-based design of inhibitors.
Blanco B; Sedes A; Peón A; Otero JM; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
J Med Chem; 2014 Apr; 57(8):3494-510. PubMed ID: 24689821
[TBL] [Abstract][Full Text] [Related]
2. Rational design of new bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
[TBL] [Abstract][Full Text] [Related]
3. Comparative binding energy COMBINE analysis for understanding the binding determinants of type II dehydroquinase inhibitors.
Peón A; Coderch C; Gago F; González-Bello C
ChemMedChem; 2013 May; 8(5):740-7. PubMed ID: 23450741
[TBL] [Abstract][Full Text] [Related]
4. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
[TBL] [Abstract][Full Text] [Related]
5. Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids.
Peón A; Otero JM; Tizón L; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Gago F; Castedo L; González-Bello C
ChemMedChem; 2010 Oct; 5(10):1726-33. PubMed ID: 20815012
[TBL] [Abstract][Full Text] [Related]
6. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
7. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
8. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic basis of the inhibition of type II dehydroquinase by (2S)- and (2R)-2-benzyl-3-dehydroquinic acids.
Lence E; Tizón L; Otero JM; Peón A; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; González-Bello C
ACS Chem Biol; 2013 Mar; 8(3):568-77. PubMed ID: 23198883
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insight into the reaction catalysed by bacterial type II dehydroquinases.
Coderch C; Lence E; Peón A; Lamb H; Hawkins AR; Gago F; González-Bello C
Biochem J; 2014 Mar; 458(3):547-57. PubMed ID: 24392963
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase.
Sánchez-Sixto C; Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2005 Jul; 48(15):4871-81. PubMed ID: 16033267
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
[TBL] [Abstract][Full Text] [Related]
13. Insights into substrate binding and catalysis in bacterial type I dehydroquinase.
Maneiro M; Peón A; Lence E; Otero JM; Van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
Biochem J; 2014 Sep; 462(3):415-24. PubMed ID: 24957267
[TBL] [Abstract][Full Text] [Related]
14. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Frederickson M; Evans DP; Coggins JR; Abell C; González-Bello C
Org Biomol Chem; 2003 Jun; 1(12):2075-83. PubMed ID: 12945898
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.
Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C
ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
[TBL] [Abstract][Full Text] [Related]
19. Irreversible covalent modification of type I dehydroquinase with a stable Schiff base.
Tizón L; Maneiro M; Peón A; Otero JM; Lence E; Poza S; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
Org Biomol Chem; 2015 Jan; 13(3):706-16. PubMed ID: 25370445
[TBL] [Abstract][Full Text] [Related]
20. Progress in type II dehydroquinase inhibitors: from concept to practice.
González-Bello C; Castedo L
Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
